National Cancer Institute Awards Labcyte $1 Million for Novel High-Throughput Cancer Biomarker Detection - - Spectroscopy
 Home   Mass Spectrometry   ICP-MS   Infrared   FT-IR   UV-Vis   Raman   NMR   X-Ray   Fluorescence  
Home
Magazine
Issue Archive
Subscribe/Renew
Special Issues
Reprints
The Application Notebook
Current Issue
Archive
Submission Guidelines
E-solutions
Digital Edition
Subscribe to the Digital Edition
The Wavelength
Subcribe to The Wavelength
Subscribe to the MS E-news
Resources
Market Profiles
Information for Authors
Lab TV
Webcasts
Advertiser services
Contact Us
Columns
Atomic Perspectives
Chemometrics in Spectroscopy
Focus on Quality
Laser and Optics Interface
Mass Spectrometry Forum
The Baseline
Molecular Spectroscopy Workbench

National Cancer Institute Awards Labcyte $1 Million for Novel High-Throughput Cancer Biomarker Detection

Spectroscopy

Labcyte, Inc. (Sunnyvale, California), an acoustic dispensing company, has been awarded $1 million to create an innovative process to detect cancer-related proteins in samples, with initial work in breast cancer detection.

Labcyte’s acoustic liquid handling enables biomarker detection by measuring multiple proteins with a MALDI mass spectrometer. Recent work with the Canary Center at Stanford (Palo Alto, California), also supported by the National Cancer Institute, showed the ability to achieve the sensitivity required for quantifying very small amounts of proteins associated with ovarian cancer. Measuring the amount of multiple proteins, and at lower cost, is an essential step in developing new diagnostic tools for disease treatment and monitoring.

“I am particularly enthusiastic about participating with Labcyte on the further development of their protein multiplexed biomarker detection platform,” Dr. Mark Stolowitz, director of the Proteomics Core Facility at the Canary Center at Stanford for Cancer Early Detection said in a statement. “This novel immunoaffinity mass spectrometry based approach exploits MALDI-TOF-MS for detection of proteotypic peptides. The platform affords sensitivity comparable to that of triple-quad mass spectrometers while providing significantly greater throughput and better precision than that obtainable from LC-MS-MS based approaches. Over the next few years, the Labcyte platform should provide the high throughput biomarker verification/validation solution that researchers have sought in conjunction with the emergence of clinical proteomics.”

In addition to working with the Canary Center, the Labcyte project includes collaboration with the Fred Hutchinson Cancer Research Center in Seattle, Washington.

Rate This Article
Your original vote has been tallied and is included in the ratings results.
View our top pages
Average rating for this page is: 0
Headlines from LCGC North America and Chromatography Online
Agilent NA - Screen Beer by GC/MS Static Headspace with the Agilent J&W DB-624 Ultra Inert Capillary Column
Waters NA - Multi-Residue Pesticide Analysis in Ginseng Powder
Agilent EU - Screen Beer by GC–MS Static Headspace with the Agilent J&W DB-624 Ultra Inert Capillary Column
Agilent NA - Analysis of Pesticide Residues in Chicken Muscle with QuEChERS and Triple Quadrupole GC
Agilent NA - Optimizing Sample Preparation for LC/MS/MS of Pesticide Residues in Herbal Teas
Source: Spectroscopy,
Click here